

The clinical decision analysis using decision tree

Jong-Myon Bae

Department of Preventive Medicine, Jeju National University School of Medicine, Jeju, Korea

The clinical decision analysis (CDA) has used to overcome complexity and uncertainty in medical problems. The CDA is a tool allowing decision-makers to apply evidence-based medicine to make objective clinical decisions when faced with complex situations. The usefulness and limitation including six steps in conducting CDA were reviewed. The application of CDA results should be done under shared decision with patients' value.

KEY WORDS: Decision analysis, Decision-making, Decision support techniques, Evidence-base medicine

INTRODUCTION

Clinical practice, aimed at solving clinical problems of individual patients, is an act of continual decision-making. The best clinical decision refers to making a choice that maximizes effectiveness and minimizes harm [1]. Nevertheless, when the supporting evidences were scant, decision-making depends on the subjective intuition of the physician and then becomes unpredictable and non-reproducible [2].

Around the 1990s, Evidence-based Medicine (EBM), which was suggested as a methodology for making clinical decisions based on the best evidence [3-6], expanded across the entire field of healthcare, and the terminology "evidence-based decision-making" was introduced [7-9]. By overcoming the complexity of medical environment [10-13] and the uncertainty of clinical decisions [14-17], the EBM aims to pursue qualitative improvements in healthcare [18-21]. Because clinical decisions are also directly related to the development and expansion of clinical treatment guidelines, approval of new drugs, drug prescriptions, the applicability of medical insurance for procedures, and healthcare policies [22,23].

Correspondence: Jong-Myon Bae
Department of Preventive Medicine, Jeju National University School of Medicine, 102 Jejudaehak-ro, Jeju 690-756, Korea
Tel: +82-64-755-5567, Fax: +82-64-725-2593, E-mail: jmbae@jejunu.ac.kr

Received: Sep 9, 2014, Accepted: Oct 29, 2014, Published: Oct 30, 2014

This article is available from: <http://e-epih.org/>

© 2014, Korean Society of Epidemiology

© This is an open-access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/3.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

McCreery & Truelove [20] summarized five methodologies for decision-making: (1) Bayes' theorem, (2) decision-tree design, (3) receiver-operating-characteristic curves, (4) sensitivity analysis, (5) utilities assessment. The clinical decision analysis (CDA) was suggested to make a clinical decision based on objectively quantitative indices calculated by using these methodologies [1]. This manuscript aims at reviewing the CDA methodology by definition, process, usefulness, and limitations.

BODY

Definition of clinical decision analysis

In 1976, Bear & Schneiderman [24] suggested the terminology "clinical decision analysis" with the intention of applying the concept of decision analysis (DA), which had already been used in business and other social sciences, to the field of clinical practice. In order to understand the meaning of the term CDA, it is necessary to also look at the term DA coined by Raiffa [25] in 1968. In Appendix 1, paragraphs defining DA and CDA were arranged chronologically. CDA can be seen as a way of overcoming 'uncertainty'.

Process of clinical decision analysis

Watts [26] proposed that CDA should consist of six stages including cost analysis, whereas Sackett et al. [27] proposed six stages including clinical practice. These process was well explained in the articles of Korah et al. [28] and Aleem et al. [1]. Depending on the methodology used, the CDA stages can be summarized as follows: (1) designing a decision tree showing all instances that can occur in a particular situation, (2) securing the



Figure 1. Steps of clinical decision analysis using decision tree method.

likelihood and outcome utility values for each instance by conducting a literature search, (3) calculating the probabilities of cumulative expectation using the Bayesian theorem, and (4) performing a sensitivity analysis and assessing the variables needed for clinical decision-making (Figure 1).

Since the content of the series of tasks that must be performed (including the construction of the decision tree) varies depending on the research questions [29], reference papers for different research questions are presented in Appendix 2. A detailed explanation is not included. Instead, the significance of performing a sensitivity analysis in the final stage will be discussed. The cumulative expectation probabilities obtained by using a decision tree vary according to the input values of outcome utility and likelihood [30]. Consequently, by estimating the vulnerability (how much the outcomes change according to fluctuations in the input values) the ultimate objective was to reduce uncertainty in decision-making [31]. In addition, sensitivity analysis could be used to elucidate the extent to which a given clinical situational variable affects the decision [28,32-34], so that these variables can be used as latent predictor variables for clinical prediction rules (CPR) [35-38]. Moreover, areas requiring future clinical research can be identified [39], and logical systematic errors in the designed decision tree can be debugged [30]. Traditional n-way sensitivity analysis [39,40] has been used as the statistical method for conducting a sensitivity analysis, but more recently, the Markov Chain Monte Carlo simulation methods [39,41-43] has been mainly used.

In the CDA process, the most difficult stages are the design of the decision tree [1,40,44-46], the debugging of logical errors in the designed tree [30], the calculation of the cumulative probability, and the Monte Carlo simulation for the sensitivity analysis [47]. The recent development of the commercial software TreeAge Pro [48] is making these processes easier, and the importance of the literature search to find the appropriate values for analysis is being emphasized [1,49]. The latter is crucial since the meaning of the relevant values varies by country and generation [50,51].

Usefulness of clinical decision analysis

The usefulness of CDA in a clinical setting, being performed with the aim of overcoming complexity and uncertainty in clinical decisions, can be broadly summarized into three types.

First, true to its original purpose, CDA provides the decision maker with objective evidence to make a judgment [1,52-55]. Consistent and reproducible decision-making can reduce the

misuse of medical resources caused by uncertainty, improve the patient-physician relationship [18,30,56], and lead to qualitative improvements in healthcare [57,58].

Second, CDA reveals the environmental variables that need to be considered when making a decision in a clinical setting [49,59,60]. This can be useful in decision-making not only for physicians, but also for medical insurance companies or decision-makers in healthcare administration [32,33,61].

Third, by elucidating these predictor variables, the sensitivity analysis can be useful for CPR development, and can be applied to utility analysis and even cost analysis, as it reveals cases of insufficient evidence [5,26,33,60,62,63].

Limitations of clinical decision analysis

It has been claimed that the results obtained by CDA using a decision tree should only be used as a reference in decision-making, and are not guaranteed as absolute [45,64]. This implies that the CDA methodology has several limitations. Since CDA was proposed in 1970, doubts have been raised about its usefulness [57]. Aleem et al. [45] have presented a summary of these limitations from the perspective of a performance and of outcome analysis: (1) simplification errors may occur when measuring the final outcome of treatment decisions with indices such as quality-adjusted life years (QALYs) [1,32,49]; (2) performing a time-consuming analysis adequately in a busy clinical environment is difficult [45]; and (3) various factors (including potential harmful, expense, and patient preference for medical services) are involved in decision-making, and these cannot be accurately reflected in a decision tree [63,65]. Therefore, even if a CDA result is available, diverse decision-making is ultimately inevitable [10,66,67].

CONCLUSION AND PROPOSALS

Although the nature of medical treatment makes diverse decision-making inevitable, Black et al. [68] nevertheless emphasize the usefulness of CDA based on its ability to overcome uncertainty in medical treatment, and because the patient will encounter objective evidence through the internet or other sources as part of the shared decisions involving the patient. Considering the trends, four suggestions would be prepared to stimulate related research in South Korea:

First, detailed care is required when interpreting the results of CDA studies and applying them to clinical practice. According

to the standards for evaluating the validity and applicability of content from CDA papers [55,69-71], not only does an appropriate evaluation need to be performed, but the predicted likelihoods as the outcomes of the analysis must also be applied to a patient group rather than to individual patients [32]. In addition, data from persons of different nationalities used for CDA have different meanings [51]. In this regard, it is necessary to conduct related studies to gain data on Korean individuals. If CDA is performed, efforts to adhere to the seven principles demanded by Lurie & Sox [72] must be made.

Second, the patients' values must be reflected in decision-making. CDA relates to the combined value of the available evidences, but EBM [73-75] emphasizes that the manner in which this evidence is interpreted and reflected in the decision depends on the experiences of the clinical team [76] and the preferences of the patient [77]. In order to synthesize these three factors, Straus [78] proposed the likelihood of being helped or harmed index. In this way, shared decisions [79,80], meaning that decisions made together with the patient, are increasingly being demanded nowadays, and there is an emphasis on patient-centered clinical service [81,82]. This is in line with the principles of medical ethics [83-85] and can achieve the goal of restricting uncertainty in clinical treatment [14,86,87].

Third, since the patient's opinion should be positively reflected in the decision-making, decision aids for patients should be developed [88-90] in addition to increased CDA research. As seen in the various examples of decision aids described by O'Connor [91], decision aids are instruments that help making a value-based decision in accordance with the patient's individual preferences but are different from educational material for patients [92]. Given that research has consistently shown that these instruments are helpful for patients [93-95], more decision aids for Korean patients must be developed.

Fourth, CDA using decision trees, as dealt with in this manuscript, became active in the 1990s, and entering the 2000s various methodologies have been developed and are being applied to healthcare and medical treatment, such as supporting vector machines [96], random forest [97], and deep learning [98]. In the future, these methodologies must be investigated, so that they may be applied to various areas in healthcare with an understanding of their strengths and weaknesses.

ACKNOWLEDGEMENTS

This research was conducted with the support of the 2014 Jeju National University Scholarship for the Promotion of Research.

CONFLICT OF INTEREST

The author has no conflicts of interest to declare for this study.

SUPPLEMENTARY MATERIAL

Supplementary material is available at <http://www.e-epih.org/>.

REFERENCES

1. Aleem IS, Schemitsch EH, Hanson BP. What is a clinical decision analysis study? *Indian J Orthop* 2008;42:137-139.
2. Banning M. A review of clinical decision making: models and current research. *J Clin Nurs* 2008;17:187-195.
3. Rosenberg WM, Sackett DL. On the need for evidence-based medicine. *Therapie* 1996;51:212-217.
4. Sackett DL. Evidence-based medicine. *Spine (Phila Pa 1976)* 1998; 23:1085-1086.
5. Djulbegovic B, Hozo I, Lyman GH. Linking evidence-based medicine therapeutic summary measures to clinical decision analysis. *Med-GenMed* 2000;2:E6.
6. Bae JM, Park BJ, Ahn YO. Perspectives of clinical epidemiology in Korea. *J Korean Med Assoc* 2013;56:718-723 (Korean).
7. Dowie J. 'Evidence-based', 'cost-effective' and 'preference-driven' medicine: decision analysis based medical decision making is the pre-requisite. *J Health Serv Res Policy* 1996;1:104-113.
8. Teutsch SM, Berger ML. Evidence synthesis and evidence-based decision making: related but distinct processes. *Med Decis Making* 2005;25:487-489.
9. Bates DW, Kuperman GJ, Wang S, Gandhi T, Kittler A, Volk L, et al. Ten commandments for effective clinical decision support: making the practice of evidence-based medicine a reality. *J Am Med Inform Assoc* 2003;10:523-530.
10. Balla JI, Elstein AS, Christensen C. Obstacles to acceptance of clinical decision analysis. *BMJ* 1989;298:579-582.
11. Hamilton JD. Do we under utilise actuarial judgement and decision analysis? *Evid Based Ment Health* 2001;4:102-103.
12. Galanter CA, Patel VL. Medical decision making: a selective review for child psychiatrists and psychologists. *J Child Psychol Psychiatry* 2005;46:675-689.
13. Thompson C, Cullum N, McCaughan D, Sheldon T, Raynor P. Nurses, information use, and clinical decision making--the real world potential for evidence-based decisions in nursing. *Evid Based Nurs* 2004; 7:68-72.
14. Beresford EB. Uncertainty and the shaping of medical decisions. *Hastings Cent Rep* 1991;21:6-11.
15. West AF, West RR. Clinical decision-making: coping with uncertainty. *Postgrad Med J* 2002;78:319-321.
16. Hu W, Kemp A, Kerridge I. Making clinical decisions when the stakes are high and the evidence unclear. *BMJ* 2004;329:852-854.
17. Thornton JG, Lilford RJ, Johnson N. Decision analysis in medicine. *BMJ* 1992;304:1099-1103.
18. Bae JM. Academic strategies based on evidence-practice gap. *Hanyang Med Rev* 2014 (in press).
19. Brazil K, Ozer E, Cloutier MM, Levine R, Stryer D. From theory to practice: improving the impact of health services research. *BMC Health*

- Serv Res 2005;5:1.
20. McCreery AM, Truelove E. Decision making in dentistry. Part I: a historical and methodological overview. *J Prosthet Dent* 1991;65:447-451.
 21. Myers J, McCabe SJ. Understanding medical decision making in hand surgery. *Clin Plast Surg* 2005;32:453-461.
 22. Atkins D. Creating and synthesizing evidence with decision makers in mind: integrating evidence from clinical trials and other study designs. *Med Care* 2007;45:S16-S22.
 23. Garrison LP Jr, Neumann PJ, Erickson P, Marshall D, Mullins CD. Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report. *Value Health* 2007;10:326-335.
 24. Bear R, Schneiderman J. Decision analysis in clinical medicine. *Can Med Assoc J* 1976;115:833-836.
 25. Raiffa H. Decision analysis; introductory lectures on choices under uncertainty. *MD Comput* 1993;10:312-328.
 26. Watts NT. Clinical decision analysis. *Phys Ther* 1989;69:569-576.
 27. Sackett DL, Haynes RB, Guyatt GH, Tugwell P. *Clinical epidemiology: a basic science for clinical medicine*. 2nd ed. Boston: Little, Brown; 1991, p. 140-145.
 28. Korah S, Thomas R, Muliylil J. An introduction to clinical decision analysis in ophthalmology. *Indian J Ophthalmol* 1999;47:41-48.
 29. Lilford RJ, Pauker SG, Braunholtz DA, Chard J. Decision analysis and the implementation of research findings. *BMJ* 1998;317:405-409.
 30. Krahn MD, Naglie G, Naimark D, Redelmeier DA, Detsky AS. Primer on medical decision analysis: part 4--analyzing the model and interpreting the results. *Med Decis Making* 1997;17:142-151.
 31. Briggs AH. Handling uncertainty in cost-effectiveness models. *Pharmacoeconomics* 2000;17:479-500.
 32. van der Velde G. Clinical decision analysis: an alternate, rigorous approach to making clinical decisions and developing treatment recommendations. *J Can Chiropr Assoc* 2005;49:258-263.
 33. Graham B, Detsky AS. The application of decision analysis to the surgical treatment of early osteoarthritis of the wrist. *J Bone Joint Surg Br* 2001;83:650-654.
 34. Hirai S, Ono J, Odaki M, Serizawa T, Sato M, Isobe K, et al. Treatment of asymptomatic unruptured intracranial aneurysms. A clinical decision analysis. *Interv Neuroradiol* 2001;7:61-64.
 35. Huijbregts P. Clinical prediction rules: time to sacrifice the holy cow of specificity? *J Man Manip Ther* 2007;15:5-8.
 36. Cook CE. Potential pitfalls of clinical prediction rules. *J Man Manip Ther* 2008;16:69-71.
 37. Ingui BJ, Rogers MA. Searching for clinical prediction rules in MEDLINE. *J Am Med Inform Assoc* 2001;8:391-397.
 38. Vickers AJ, Cronin AM. Traditional statistical methods for evaluating prediction models are uninformative as to clinical value: towards a decision analytic framework. *Semin Oncol* 2010;37:31-38.
 39. Aoki N, Beck JR, Kitahara T, Ohbu S, Soma K, Ohwada T, et al. Re-analysis of unruptured intracranial aneurysm management: effect of a new international study on the threshold probabilities. *Med Decis Making* 2001;21:87-96.
 40. Hagen MD. Decision analysis: a review. *Fam Med* 1992;24:349-354.
 41. Minelli C, Abrams KR, Sutton AJ, Cooper NJ. Benefits and harms associated with hormone replacement therapy: clinical decision analysis. *BMJ* 2004;328:371.
 42. Naimark D, Krahn MD, Naglie G, Redelmeier DA, Detsky AS. Primer on medical decision analysis: part 5--Working with Markov processes. *Med Decis Making* 1997;17:152-159.
 43. Doubilet P, Begg CB, Weinstein MC, Braun P, McNeil BJ. Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach. *Med Decis Making* 1985;5:157-177.
 44. Podgorelec V, Kokol P, Stiglic B, Rozman I. Decision trees: an overview and their use in medicine. *J Med Syst* 2002;26:445-463.
 45. Aleem IS, Jalal H, Aleem IS, Sheikh AA, Bhandari M. Clinical decision analysis: incorporating the evidence with patient preferences. *Patient Prefer Adherence* 2009;3:21-24.
 46. Detsky AS, Naglie G, Krahn MD, Redelmeier DA, Naimark D. Primer on medical decision analysis: part 2--building a tree. *Med Decis Making* 1997;17:126-135.
 47. Doan A, Haddawy P, Kahn CE Jr. Decision-theoretic refinement planning: a new method for clinical decision analysis. *Proc Annu Symp Comput Appl Med Care* 1995:299-303.
 48. TreeAge Software Inc. *TreeAge pro healthcare* [cited 2014 Sep 9]. Available from: <https://www.treeage.com/shop/treeage-pro-healthcare/>.
 49. Naglie G, Krahn MD, Naimark D, Redelmeier DA, Detsky AS. Primer on medical decision analysis: part 3--Estimating probabilities and utilities. *Med Decis Making* 1997;17:136-141.
 50. Torrance GW. Utility approach to measuring health-related quality of life. *J Chronic Dis* 1987;40:593-603.
 51. Clancy CM, Cronin K. Evidence-based decision making: global evidence, local decisions. *Health Aff (Millwood)* 2005;24:151-162.
 52. Sarasin FP. Decision analysis and its application in clinical medicine. *Eur J Obstet Gynecol Reprod Biol* 2001;94:172-179.
 53. Yentis SM. Decision analysis in anaesthesia: a tool for developing and analysing clinical management plans. *Anaesthesia* 2006;61:651-658.
 54. Sisson JC, Schoemaker EB, Ross JC. Clinical decision analysis. The hazard of using additional data. *JAMA* 1976;236:1259-1263.
 55. Richardson WS, Detsky AS. Users' guides to the medical literature. VII. How to use a clinical decision analysis. A. Are the results of the study valid? Evidence-Based Medicine Working Group. *JAMA* 1995;273:1292-1295.
 56. Kassirer JP, Moskowitz AJ, Lau J, Pauker SG. Decision analysis: a progress report. *Ann Intern Med* 1987;106:275-291.
 57. Dolan JG. Clinical decision analysis. *Med Decis Making* 2001;21:150-151.
 58. Pauker SG, Kassirer JP. Decision analysis. *N Engl J Med* 1987;316:250-258.
 59. Stockstill JW, Bowley JF, Attanasio R. Clinical decision analysis in fixed prosthodontics. *Dent Clin North Am* 1992;36:569-580.
 60. McCreery AM, Truelove E. Decision making in dentistry. Part II: clinical applications of decision methods. *J Prosthet Dent* 1991;65:575-585.
 61. Burd RS, Sonnenberg FA. Decision analysis: a basic overview for the pediatric surgeon. *Semin Pediatr Surg* 2002;11:46-54.
 62. Burford B, Lewin S, Welch V, Rehfuss E, Waters E. Assessing the applicability of findings in systematic reviews of complex interventions can enhance the utility of reviews for decision making. *J Clin Epidemiol* 2013;66:1251-1261.
 63. Burch J, Hinde S, Palmer S, Beyer F, Minton J, Marson A, et al. The clinical effectiveness and cost-effectiveness of technologies used to visualise the seizure focus in people with refractory epilepsy being considered for surgery: a systematic review and decision-analytical model. *Health Technol Assess* 2012;16:1-157.
 64. Buchanan JG. An introduction to clinical decision analysis: bone marrow transplantation for aplastic anemia. *Aust N Z J Med* 1983;13:451-456.
 65. Bhandari M, Devereaux PJ, Swiontkowski MF, Tornetta P 3rd, Obrebsky W, Koval KJ, et al. Internal fixation compared with arthroplasty for displaced fractures of the femoral neck. A meta-analysis. *J Bone Joint Surg Am* 2003;85-A:1673-1681.

66. Brookhart MA, Solomon DH, Wang P, Glynn RJ, Avorn J, Schneeweiss S. Explained variation in a model of therapeutic decision making is partitioned across patient, physician, and clinic factors. *J Clin Epidemiol* 2006;59:18-25.
67. Sekimoto M, Imanaka Y, Kitano N, Ishizaki T, Takahashi O. Why are physicians not persuaded by scientific evidence? A grounded theory interview study. *BMC Health Serv Res* 2006;6:92.
68. Blank T, Graves K, Sepucha K, Llewellyn-Thomas H. Understanding treatment decision making: contexts, commonalities, complexities, and challenges. *Ann Behav Med* 2006;32:211-217.
69. Brocklehurst P, Roberts T. Should acyclovir prophylaxis be used in late pregnancy in women with recurrent genital herpes infection? How to use a clinical decision analysis. *Genitourin Med* 1997;73:314-319.
70. Richardson WS, Detsky AS. Users' guides to the medical literature. VII. How to use a clinical decision analysis. B. What are the results and will they help me in caring for my patients? Evidence Based Medicine Working Group. *JAMA* 1995;273:1610-1613.
71. Thornhill J, Judd M, Clements D. CHSRF knowledge transfer: (re) introducing the self-assessment tool that is helping decision-makers assess their organization's capacity to use research. *Healthc Q* 2009; 12:22-24.
72. Lurie JD, Sox HC. Principles of medical decision-making. *Spine* 1999;24:493-498.
73. Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn't. *BMJ* 1996;312: 71-72.
74. Barratt A. Evidence Based Medicine and Shared Decision-making: the challenge of getting both evidence and preferences into health care. *Patient Educ Couns* 2008;73:407-412.
75. Tilburt JC. Evidence-based medicine beyond the bedside: keeping an eye on context. *J Eval Clin Pract* 2008;14:721-725.
76. Dans AL, Dans LF, Guyatt GH, Richardson S. Users' guides to the medical literature: XIV. How to decide on the applicability of clinical trial results to your patient. Evidence-Based Medicine Working Group. *JAMA* 1998;279:545-549.
77. Goetghebuer MM, Wagner M, Khoury H, Levitt RJ, Erickson LJ, Rindress D. Evidence and Value: impact on DEcisionMaking--the EVIDEM framework and potential applications. *BMC Health Serv Res* 2008;8:270.
78. Straus SE. Individualizing treatment decisions. The likelihood of being helped or harmed. *Eval Health Prof* 2002;25:210-224.
79. Godolphin W. Shared decision-making. *Healthc Q* 2009;12 Spec No Patient:e186-e190.
80. Bate L, Hutchinson A, Underhill J, Maskrey N. How clinical decisions are made. *Br J Clin Pharmacol* 2012;74:614-620.
81. Barry MJ, Edgman-Levitan S. Shared decision-making--pinnacle of patient-centered care. *N Engl J Med* 2012;366:780-781.
82. Oshima Lee E, Emanuel EJ. Shared decision-making to improve care and reduce costs. *N Engl J Med* 2013;368:6-8.
83. ter Meulen RH. The ethical basis of the precautionary principle in health care decision-making. *Toxicol Appl Pharmacol* 2005;207:663-667.
84. Tannahill A. Beyond evidence--to ethics: a decision-making framework for health promotion, public health and health improvement. *Health Promot Int* 2008;23:380-390.
85. Berger JT, DeRenzo EG, Schwartz J. Surrogate decision-making: reconciling ethical theory and clinical practice. *Ann Intern Med* 2008; 149:48-53.
86. Kass NE. Early phase clinical trials: communicating the uncertainties of 'magnitude of benefit' and 'likelihood of benefit'. *Clin Trials* 2008; 5:627-629.
87. Légaré F, Brouillette MH. Shared decision-making in the context of menopausal health: where do we stand? *Maturitas* 2009;63:169-175.
88. Légaré F, Moher D, Elwyn G, LeBlanc A, Gravel K. Instruments to assess the perception of physicians in the decision-making process of specific clinical encounters: a systematic review. *BMC Med Inform Decis Mak* 2007;7:30.
89. Stacey D, Samant R, Bennett C. Decision-making in oncology: a review of patient decision aids to support patient participation. *CA Cancer J Clin* 2008;58:293-304.
90. Elwyn G, Stiel M, Durand MA, Boivin J. The design of patient decision support interventions: addressing the theory-practice gap. *J Eval Clin Pract* 2011;17:565-574.
91. O'Connor A. Using patient decision aids to promote evidence-based decision-making. *ACP J Club* 2001;135:A11-A12.
92. O'Connor AM. Using decision aids to help patients navigate the "grey zone" of medical decision-making. *CMAJ* 2007;176:1597-1598.
93. Roshanov PS, Fernandes N, Wilczynski JM, Hemens BJ, You JJ, Handler SM, et al. Features of effective computerised clinical decision support systems: meta-regression of 162 randomised trials. *BMJ* 2013; 346:f657.
94. O'Connor AM, Bennett C, Stacey D, Barry MJ, Col NF, Eden KB, et al. Do patient decision aids meet effectiveness criteria of the international patient decision aid standards collaboration? A systematic review and meta-analysis. *Med Decis Making* 2007;27:554-574.
95. Liu J, Wyatt JC, Altman DG. Decision tools in health care: focus on the problem, not the solution. *BMC Med Inform Decis Mak* 2006; 6:4.
96. Chen T, Wang Y, Chen H, Marder K, Zeng D. Targeted local support vector machine for age-dependent classification. *J Am Stat Assoc* 2014;109:1174-1187.
97. Breiman L. Random forests. *Mach Learn* 2001;45:5-32.
98. Hinton GE, Osindero S, Teh YW. A fast learning algorithm for deep belief nets. *Neural Comput* 2006;18:1527-1554.

Appendix 1. Summary tables of the definition-related sentences about decision analysis (DA) and clinical decision analysis (CDA)

Sources references		Related sentences
DA	A01	DA -an explicit, normative and analytic approach to making decisions under uncertainty- provides a probabilistic framework for exploring difficult problems in <u>non-deterministic domains</u> .
	A02	DA is the application of explicit, quantitative methods to analyze decisions under <u>conditions of uncertainty</u> .
	A03	DA formalizes the decision process, highlights the factors that influence the decision, and applies mathematical rigour to quantify decision-making.
CDA	A04	CDA seeks to identify the optimal management strategy by modelling the <u>uncertainty</u> and risks entailed in the diagnosis, natural history, and treatment of a particular problem or disorder.
	A05	CDA is a systematic method for making wise choices under just such circumstances.
	A06	(C)DA in a quantitative approach for dealing with the <u>uncertainties</u> inherent in many medical decisions, including decisions about genetic testing.
	A07	(C)DA is a quantitative by an ever increasing number of costly and confusing application of probability and utility theory to decision diagnostic tests and therapeutic interventions, decision-making under conditions of <u>uncertainty</u> .
	A08	(C)DA is a quantitative approach to decision-making under conditions of <u>uncertainty</u> that can be applied to specific types of clinical problems.
	A09	CDA is a process whereby different treatment options are assessed systematically.
	A10	(C)DA is a formal, mathematical approach to analyzing difficult decisions faced by clinical decision makers (i.e. patients, clinicians, policy-makers).
	A11	(C)DA is a formal, quantitative method for systematically comparing the benefits and harms of alternative clinical strategies under circumstances of <u>uncertainty</u> .
	A12	(C)DA is a tool that allows users to apply evidence-based medicine to make informed and objective clinical decisions when faced with complex situations.
	A13	(C)DA is a simulation, model-based research technique in which investigators combine information from a variety of sources to create a mathematical model representing a clinical decision.
	A14	CDA – the application of DA to a clinical or patient-based setting – is a technique that incorporates literature-derived probabilities with expert and patient preferences to result in an informed clinical decision.

- A01. Wong JB, Moskowitz AJ, Pauker SG. Clinical decision analysis using microcomputers. A case of coexistent hepatocellular carcinoma and abdominal aortic aneurysm. *West J Med* 1986;145:805-815.
- A02. Richardson WS, Detsky AS. Users' guides to the medical literature. VII. How to use a clinical decision analysis. A. Are the results of the study valid? Evidence-Based Medicine Working Group. *JAMA* 1995;273:1292-1295.
- A03. Sonnenberg A. Patient-physician discordance about benefits and risks in gastroenterology decision-making. *Aliment Pharmacol Ther* 2004;19:1247-1253.
- A04. Doan A, Haddawy P, Kahn CE Jr. Decision-theoretic refinement planning: a new method for clinical decision analysis. *Proc Annu Symp Comput Appl Med Care* 1995:299-303.
- A05. Watts NT. Clinical decision analysis. *Phys Ther* 1989;69:569-576.
- A06. McConnell LM, Goldstein MK. The application of medical decision analysis to genetic testing: an introduction. *Genet Test* 1999;3:65-70.
- A07. Sarasin FP. Decision analysis and its application in clinical medicine. *Eur J Obstet Gynecol Reprod Biol* 2001;94:172-179.
- A08. Burd RS, Sonnenberg FA. Decision analysis: a basic overview for the pediatric surgeon. *Semin Pediatr Surg* 2002;11:46-54.
- A09. Manarey CR, Westerberg BD, Marion SA. Clinical decision analysis in the treatment of acute otitis media in a child over 2 years of age. *J Otolaryngol* 2002;31:23-30.
- A10. van der Velde G. Clinical decision analysis: an alternate, rigorous approach to making clinical decisions and developing treatment recommendations. *J Can Chiropr Assoc* 2005;49:258-263.
- A11. Elkin EB, Vickers AJ, Kattan MW. Primer: using decision analysis to improve clinical decision-making in urology. *Nat Clin Pract Urol* 2006;3:439-448.
- A12. Aleem IS, Schemitsch EH, Hanson BP. What is a clinical decision analysis study? *Indian J Orthop* 2008;42:137-139.
- A13. O'Brien SH. Decision analysis in pediatric hematology. *Pediatr Clin North Am* 2008;55:287-304.
- A14. Aleem IS, Jalal H, Aleem IS, Sheikh AA, Bhandari M. Clinical decision analysis: incorporating the evidence with patient preferences. *Patient Prefer Adherence* 2009;3:21-24.

Appendix 2. Articles referring to conducting clinical decision analysis using decision tree method

Epidemiology	Domain	Related publications
Basic	Threshold	B01, B02
	Prognostic factor	B03
	Cost factor	B04
	Genetic counseling	B05
Clinical	Screening test	B06
	Diagnostic test	B07, B08
	Procedures	B09-B13
	Drug	B14, B15

- B01. Pauker SG, Kassirer JP. The threshold approach to clinical decision-making. *N Engl J Med* 1980;302:1109-1117.
- B02. Harber P, Rappaport S. Clinical decision analysis in occupational medicine. Choosing the optimal FEV1 criterion for diagnosing occupational asthma. *J Occup Med* 1985;27:651-658.
- B03. Gando S, Nanzaki S, Kemmotsu O. Disseminated intravascular coagulation and sustained systemic inflammatory response syndrome predict organ dysfunctions after trauma: application of clinical decision analysis. *Ann Surg* 1999;229:121-127.
- B04. Connock M, Frew E, Evans BW, Bryan S, Cummins C, Fry-Smith A, et al. The clinical effectiveness and cost-effectiveness of newer drugs for children with epilepsy. A systematic review. *Health Technol Assess* 2006;10:1-118.
- B05. Pauker SP, Pauker SG. Prenatal diagnosis: a directive approach to genetic counseling using decision analysis. *Yale J Biol Med* 1977;50:275-289.
- B06. Krahn MD, Mahoney JE, Eckman MH, Trachtenberg J, Pauker SG, Detsky AS. Screening for prostate cancer. A decision analytic view. *JAMA* 1994;272:773-780.
- B07. Mol BW, Verhagen TE, Hendriks DJ, Collins JA, Coomarasamy A, Opmeer BC, et al. Value of ovarian reserve testing before IVF: a clinical decision analysis. *Hum Reprod* 2006;21:1816-1823.
- B08. Burch J, Hinde S, Palmer S, Beyer F, Minton J, Marson A, et al. The clinical effectiveness and cost-effectiveness of technologies used to visualise the seizure focus in people with refractory epilepsy being considered for surgery: a systematic review and decision-analytical model. *Health Technol Assess* 2012;16:1-157.
- B09. Johnson N, Lilford RJ, Jones SE, McKenzie L, Billingsley P, Songane FF. Using decision analysis to calculate the optimum treatment for microinvasive cervical cancer. *Br J Cancer* 1992;65:717-722.
- B10. Garipey AM, Creinin MD, Schwarz EB, Smith KJ. Reliability of laparoscopic compared with hysteroscopic sterilization at 1 year: a decision analysis. *Obstet Gynecol* 2011;118:273-279.
- B11. Aoki N, Beck JR, Kitahara T, Ohbu S, Soma K, Ohwada T, et al. Reanalysis of unruptured intracranial aneurysm management: effect of a new international study on the threshold probabilities. *Med Decis Making* 2001;21:87-96.
- B12. Liu D, Lehmann HP, Frick KD, Carter HB. Active surveillance versus surgery for low risk prostate cancer: a clinical decision analysis. *J Urol* 2012;187:1241-1246.
- B13. Willis SR, Ahmed HU, Moore CM, Donaldson I, Emberton M, Miners AH, et al. Multiparametric MRI followed by targeted prostate biopsy for men with suspected prostate cancer: a clinical decision analysis. *BMJ Open* 2014;4:e004895.
- B14. Minelli C, Abrams KR, Sutton AJ, Cooper NJ. Benefits and harms associated with hormone replacement therapy: clinical decision analysis. *BMJ* 2004;328:371.
- B15. Perreault S, Levinton C, Laurier C, Moride Y, Ste-Marie LG, Crott R. Validation of a decision model for preventive pharmacological strategies in postmenopausal women. *Eur J Epidemiol* 2005;20:89-101.